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Abstract
Association tests that pool minor alleles into a measure of burden at a locus have been proposed for case-control studies
using sequence data containing rare variants. However, such pooling tests are not robust to the inclusion of neutral and
protective variants, which can mask the association signal from risk variants. Early studies proposing pooling tests dismissed
methods for locus-wide inference using nonnegative single-variant test statistics based on unrealistic comparisons.
However, such methods are robust to the inclusion of neutral and protective variants and therefore may be more useful
than previously appreciated. In fact, some recently proposed methods derived within different frameworks are equivalent to
performing inference on weighted sums of squared single-variant score statistics. In this study, we compared two existing
methods for locus-wide inference using nonnegative single-variant test statistics to two widely cited pooling tests under
more realistic conditions. We established analytic results for a simple model with one rare risk and one rare neutral variant,
which demonstrated that pooling tests were less powerful than even Bonferroni-corrected single-variant tests in most
realistic situations. We also performed simulations using variants with realistic minor allele frequency and linkage
disequilibrium spectra, disease models with multiple rare risk variants and extensive neutral variation, and varying rates of
missing genotypes. In all scenarios considered, existing methods using nonnegative single-variant test statistics had power
comparable to or greater than two widely cited pooling tests. Moreover, in disease models with only rare risk variants, an
existing method based on the maximum single-variant Cochran-Armitage trend chi-square statistic in the locus had power
comparable to or greater than another existing method closely related to some recently proposed methods. We conclude
that efficient locus-wide inference using single-variant test statistics should be reconsidered as a useful framework for
devising powerful association tests in sequence data with rare variants.
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Introduction
The advent of high-throughput sequencing technologies is
providing an unprecedented opportunity to examine the associ-
ation of both common and rare variation with disease on an
exome-wide, and soon genome-wide, scale. In this study, we
consider the problem of using sequence data from a case-control
sample to perform a test for association between a disease and a
locus, which we define as a region of contiguous sequence
including many variants (i.e., polymorphic sequence positions).
These variants may be either common or rare; those with minor
allele frequencies (MAFs) ,2–3% [1] are termed rare variants,
and those with higher MAFs are termed common variants. Under
the null hypothesis of no association with the locus, all multi-
variant genotypes have the same disease risk. This implies that
cases and controls have equal multi-variant genotype frequencies,
and therefore single-variant genotype frequencies, at the locus
under the null hypothesis. Under the alternative hypothesis, multi-
variant genotypes have disease risks depending on one or more
variants in the locus, meaning that multi-variant genotype
frequencies differ between cases and controls at the locus.
To mitigate the power loss due to allelic heterogeneity [1–4]
and high dimensionality in this scenario, conventional wisdom
suggests that pooling minor alleles at rare variants into a measure
of burden at a locus will be necessary to detect associations [4–6].
Tests based on either collapsing rare variants in a locus into a
single indicator of the presence of any minor alleles [5,7] or
summing weighted minor allele counts over rare, and sometimes
also common, variants in a locus [6,8–10] have been proposed as
alternatives to single-variant tests. We subsequently refer to
techniques involving collapsing or summing as pooling tests.
Two of the earliest proposals, the Combined Multivariate and
Collapsing (CMC) method [5] for collapsing and the Weighted
Sum Statistic (WSS) method [6] for summing, are commonly used
as benchmarks for novel methods in the rare variant association
testing literature [8–13] based on results suggesting that these
techniques were superior to locus-wide inference using single-
variant test statistics.
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disequilibrium (LD) patterns in sequence data. Simulations using
a coalescent approximation to a neutral two-locus Wright-Fisher
infinite allele model have shown that a substantial proportion of
the pairwise LD between biallelic variants can be expected to be
negative (i.e., D,0), even at very high levels of recombination
[14]. Most importantly for sequence data, negative pairwise LD
values become more likely when including variants with relatively
rare minor alleles [14]. To the extent that there is negative LD
between neutral and risk variants within a locus, higher MAFs at a
small number of risk variants in cases will be accompanied by
higher MAFs at a larger number of neutral variants in controls. In
this situation, case-control differences in the MAFs at individual
risk variants may actually be masked by those at a large number of
neutral variants in locus-wide summaries based on collapsing or
summing minor alleles over all variants at a locus. Masking, in
turn, reduces the power of pooling tests by obscuring locus-wide
case-control differences. Such masking and power loss will be
exacerbated by the inclusion of protective variants.
Because pooling tests lose power when neutral and protective
variants are included, one sensible approach is to try to exclude
such variants a priori by filtering on annotation and functional
predictions. However, making such exclusions with high sensitivity
and specificity will be difficult, particularly in non-coding regions
for which little information is available. Even in coding regions,
functional predictions may lead researchers astray. For example,
recent studies have implicated synonymous variants in altering the
function of protein products [15] and causing disease [16]. Thus,
methods for locus-wide inference that are inherently robust to the
inclusion of neutral and protective variants are desirable.
Existing methods for locus-wide inference using nonnegative
single-variant test statistics, such as performing joint inference
based on the maximum Cochran-Armitage trend chi-square
statistic in the locus, are inherently robust to the inclusion of
neutral and protective variants. This robustness arises from the
fact that the locus-wide inference depends on only the magnitude
of the deviation from the null hypothesis at each variant and not
the direction. Joint inference can be performed efficiently by using
permutation, which, by simulating draws from the joint null
distribution of the single-variant test statistics, avoids conservative
approximations (e.g., the Bonferroni correction) and accounts for
LD-induced correlations between test statistics [17]. Existing
methods that perform efficient locus-wide inference on nonneg-
ative single-variant test statistics using permutation can therefore
combine information across variants in a locus without masking.
Such methods may also be able to extract additional association
signal from neutral variants in negative LD with risk variants as
well as protective variants. Finally, such methods allow use of all
available data when genotypes are missing completely at random
in the sense of Little and Rubin [18], which is not necessarily true
of pooling tests.
Nonetheless, many novel methods have not departed from the
pooling test framework but rather attempted to devise improved
weighting schemes and adaptive thresholds that reduce the
influence of neutral and protective variants [8–10,13]. Despite
deriving their approaches within fundamentally different frame-
works, some of the newest methods that are robust to the inclusion
of neutral and protective variants have actually arrived at
procedures equivalent to performing locus-wide inference using
nonnegative single-variant test statistics. For example, the
Sequence Kernel Association Test (SKAT) [13] and the C-alpha
test [12] base inference on weighted and unweighted sums of
squared single-variant score statistics, respectively [13]. Under an
additive genetic model without covariates and with variant weights
equal to the inverse of the estimated null variance of each single-
variant score statistic, the SKAT statistic is simply the sum of
single-variant Cochran-Armitage trend chi-square statistics. Sums
of nonnegative single-variant test statistics have previously been
recommended as powerful methods for joint inference over
multiple variants in candidate gene association studies [19] and
genome-wide association studies (GWAS) [20,21]. The equiva-
lence of new developments to existing methods for efficient locus-
wide inference using nonnegative single-variant test statistics
argues for broader investigation of other existing methods falling
within this framework, such as permutation inference on the
maximum single-variant Cochran-Armitage trend chi-square
statistic in the locus.
In this study, we compared two existing methods for locus-wide
inference using nonnegative single-variant test statistics to the two
originally proposed pooling tests [5,6] under more realistic
conditions. We began by examining the characteristics of variants
appearing in actual candidate gene sequence data. We then
illustrated with analytic power calculations using a simple model
how pooling tests may have lower power than even Bonferroni-
corrected single-variant tests in the presence of neutral variants.
We finally extended the basic conclusions of this simple model to
more complex situations with allelic heterogeneity, extensive
neutral variation, and randomly missing genotype data using
simulations based on variants with realistic MAF and LD spectra.
In these simulations, we compared the locus-wide type I error and
power of a Bonferroni-corrected test based on the maximum
single-variant Cochran-Armitage trend chi-square statistic, effi-
cient permutation tests based on the maximum or sum of single-
variant Cochran-Armitage trend chi-square statistics, the CMC
test, and the WSS test. We found that methods for efficient locus-
wide inference using nonnegative single-variant test statistics
performed as well as, and often better than, the CMC and WSS
tests under a variety of scenarios. For disease models with only rare
risk variants, we observed that the permutation test based on the
maximum of single-variant Cochran-Armitage trend chi-square
statistics had power comparable to or greater than the permuta-
tion test based on the sum, which we show is closely related to the
SKAT and C-alpha test. We conclude that efficient locus-wide
inference using nonnegative single-variant test statistics should be
reconsidered as a useful framework for devising powerful
association tests in sequence data with rare variants.
Methods
Characteristics of Variants in Actual Sequence Data
To ground our interpretation of analytic power approximations
in actual data and provide a basis for evaluating the realism of our
simulated data, we estimated the MAF and LD distributions of
variants in resequencing data from six genes (CSRP3, LDB3,
MYH7, SCN5A, TCAP, and TNNT2) previously obtained for a
study of candidate genes for dilated cardiomyopathy [22]. These
data should provide a useful snapshot of sequence-level variation
within protein-coding genes of a wide range of sizes (3 kb–103 kb),
numbers of exons (2–40), and chromosomal locations (1q32, 3p21,
10q22.3–23.2, 11p15.1, 14q12, and 17q12). Bi-directional Sanger
sequencing of all coding sequence, at least 50 bp into 59-/39-
UTRs, and at least 40 bp into all introns was performed by
SeattleSNPs under contract to the National Heart, Lung, and
Blood Institute resequencing service. We used data from 184
unrelated controls of European descent from the Coriell database
with variant call rates $80% after removal of low-quality variants
called in ,80% of individuals in the study. We considered biallelic
variants with no evidence of deviation from Hardy-Weinberg
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including both SNPs and small insertions/deletions, in calculating
the MAF and LD distributions. Pairwise LD measured by the
correlation coefficient between major alleles, r, was calculated only
between variants within the same gene under the assumption of
HWE using the method of Weir and Cockerham [23] as
implemented in PROC ALLELE, SAS/GENETICS, Version
9.2 (SAS Institute Inc., Cary, NC). This correlation coefficient is
the same as the correlation coefficient between minor alleles for a
biallelic variant.
Impact of Neutral Variation in a Simple Model
We began by examining the relative performance of pooling
tests and locus-wide inference using nonnegative single-variant test
statistics in a simple model of a locus comprising one rare risk
variant and one rare neutral variant. Specifically, we compared
the locus-wide analytic power of collapsing and summing to that of
performing Bonferroni-corrected inference on the maximum
single-variant Cochran-Armitage trend chi-square statistic in the
locus (the BC-CA test) under our model at varying levels of LD.
The Cochran-Armitage test for a single variant is well-known in
the field of genetics [24–26]. It possesses some desirable properties,
including robustness to departures from HWE [24] and ease of
calculation, that make it widely applicable. Suppose that we
independently sample R cases and S controls, and let N=R+S.I t
will be convenient for subsequent exposition to present the test
statistic T as a generalization of the form presented in Freidlin et
al. [26] to multi-variant genotypes:
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In (1), Xk is a score corresponding to the k
th single- or multi-variant
genotype, denoted Gk=[G1k,…,Gvk], comprising v biallelic
variants indexed by j. We also let rk be the number of cases with
genotype Gk, sk be the number of controls with genotype Gk, and
nk=r k+sk. The single-variant genotype at biallelic variant j in multi-
variant genotype Gk is coded as Gjk=0, 1, or 2 minor alleles.
Thus, multi-variant genotype k denotes one unique combination of
single-variant genotypes (e.g., Gk=[0,0,1,2] for v=4 and one
particular k) in the set of all w=3
v possible combinations at each of
the v variants (i.e., k=1,2,…, 3
v-1,3
v). If we consider a single
variant and use scores equaling the number of minor alleles at that
variant, we have Gk~ G1k ½  , k=1 ,2 ,o r3 ,a n dXk~G1k,s oT in
(1) reduces to the single-variant Cochran-Armitage trend chi-
square statistic.
A simple model of a locus comprising one rare neutral (j=1)
and one rare risk (j=2) biallelic variant with the same MAF (p) was
used. In this model, frequencies of haplotypes [h1,h2] for a given
level of LD (D) were calculated as (1-p)
2+D for haplotype [0,0], (1-
p)p-D for haplotypes [0,1] and [1,0], and p
2+D for haplotype [1,1],
where 1 denotes the minor allele and 0 the major allele at either
variant. Population frequencies of multi-variant genotypes
Gk=[G1k,G2k], denoted by pk, were then determined under
HWE. A multiplicative risk model, PA jGk ðÞ ~f0cG2k, was used,
with A or C denoting affection status (affected case or control), f0
denoting the penetrance for the variant 2 major allele homozy-
gote, and c denoting the relative risk for an additional minor allele
at variant 2. The conditional frequencies of each Gk in cases (pk|A)
and controls (pk|C) were determined based on this risk model and
population multi-variant genotype frequencies using Bayes’ rule:
pkjA~PA jGk ðÞ pk
.X
k PA jGk ðÞ pk
pkjC~ 1{PA jGk ðÞ ½  pk
.X
k 1{PA jGk ðÞ ½  pk
Under the generalization in (1) and the assumed sampling model,
r1,...,rw ðÞ *Multinomial R;p1jA,...,pwjA
  
and s1,',sw ðÞ *
Multinomial S;p1jC,:::,pwjC
  
. The null hypothesis that no variant
in the locus influences disease risk implies that PA jGk ðÞ ~f0 and
pkjA~pkjC~pk for all k. Under the alternative hypothesis, at least
one variant in the locus influences disease risk, implying that
pkjA=pkjC for some k.
Freidlin et al. [26] provide formulas for the variance under this
null hypothesis as well as the expectation and variance under this
alternative hypothesis for the statistic U in (1) with arbitrary scores
Xk when v=1. These formulas immediately generalize to
multinomial genotype distributions with more than 3 possible
genotypes (w.3):
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Under the null hypothesis, the asymptotic distribution of U is
N0 , Ns2
0
  
, and ^ s s2
0 defined in (1) converges in probability to s2
0
[26]. Thus, T has the same asymptotic x2
1 null distribution as
U2 
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0 by Slutsky’s Theorem because s2
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asymptotic distribution of U is N Nma,Ns2
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Thus, the asymptotic power function for any two-sided test based
on T with type I error rate a is:
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We show in Appendix A (Text S1) that particular choices of
scores Xk in the statistic T yield a single-variant Cochran-Armitage
trend test, a collapsing test, and a summing test. This corres-
pondence allows us to use the generalized formulas presented
above to approximate the locus-wide asymptotic power of each
approach to association testing in our model. The single-variant
trend test uses Xk~Gjk for variant j; collapsing defines
Xk~I
P
j Gjk~0
  
, where I(E)=1 if E is true and 0 otherwise;
and summing defines Xk~
P
j Gjk. A slight modification is
required to approximate the locus-wide power of the BC-CA test
in the presence of LD because calculating the joint distribution of
the single-variant test statistics is analytically intractable. In
Appendix B (Text S1), we establish that a lower bound for the
locus-wide power function of the BC-CA test is the power of the
Bonferroni-corrected Cochran-Armitage trend test for the risk
variant alone.
We examined power as a function of r~D
  ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p2 1{p ðÞ
2
q
for
f0=0.05 and two types of rare variant pairs (p=0.005 and c=3;
p=0.01 and c=2). Balanced case-control samples with total sizes
of N=500, 1,000, and 2,000 were considered. Values of r were
chosen by taking 100 evenly spaced increments of D starting from
Dmin=2p
2 and ending at Dmax=p(1-p).
Monte Carlo Simulations
WeusedMonteCarlosimulationstoextendtheconclusionsdrawn
fromthe two-variant locus model to a larger locus with heterogeneous
risk alleles, extensive neutral variation, realistic LD patterns, and
randomly missing genotype data. We begin by outlining the major
components of the simulation procedure and subsequently provide
more detailed exposition for each component. One thousand
populations of haplotypes at a 100 kb locus with realistic MAF and
LD spectra were first generated based on a neutral coalescent model.
Using the same 1,000 haplotype populations, a separate simulation
was then conducted for each combination of user-specified risk
variant parameters and sample size. Within each simulation:
1) The disease model for each haplotype population was
generated by randomly selecting risk variants for inclusion
based on user-specified parameters;
2) A case-control sample was drawn from each haplotype
population according to the disease model and a user-
specified sample size;
3) Data sets with randomly missing genotypes were generated
from each sample for each user-specified call rate; and
4) All association testing techniques were applied to each data
set.
Type I error and power for each technique were estimated for
balanced case-control samples of total sizes N=500, 1,000, and
2,000. The disease risk for the multi-variant genotype with no
minor alleles at any risk variant was 5% for all simulations. For
power, 50 risk variants with independent effects were randomly
selected in each haplotype population under three different disease
models:
1) Multiple rare risk variants (MAF,0.005; odds ratio
(OR)=3);
2) Multiple rare risk variants (MAF,0.01; OR=2);
3) Combinations of multiple rare risk variants (MAF,0.01;
OR=2), low-frequency risk variants (0.01#MAF,0.05;
OR=1.5), and common risk variants (0.05#MAF,0.10;
OR=1.2).
The first two models represent situations in which pooling tests
are expected to perform best, and the third model is included to
consider cases where both common and rare variants might
contribute to disease susceptibility. We chose a number risk variants
that represented ,5% of all variants at the locus in the average
haplotype population to reflect a situation in which associations
between the locus and disease were driven by heterogeneous risk
alleles characterized by a small number of risk variants among a
much larger number of neutral variants. Per-position genotype call
rates of 100% (complete data), 99.5%, and 95% were simulated. In
the following subsections, we provide a detailed description of each
component of the simulation procedure.
Haplotype Populations
One thousand populations of 10,000 haplotypes each were
generated at a 100 kb locus, which is representative of a larger
human protein coding gene based on recent data (mean size:
27 kb, range: 1 kb–2,400 kb) [29]. Haplotype populations were
generated according to a standard neutral coalescent approxima-
tion to the Wright-Fisher model with a finite-sites recombination
model and an infinite-sites mutation model, which is most accurate
when the number of haplotypes sampled is small relative to the
number of haplotypes in the population and the recombination
rate between adjacent bases is small [30,31]. We used a per-
nucleotide neutral mutation rate of 2.5610
28 estimated assuming
an effective diploid population size of Ne<10,000 [32], a
recombination rate of 1610
28 between adjacent nucleotides
derived by using the approximation 1 cM<1 Mb [33], and
Ne=10,000 (i.e., 20,000 haplotypes). We used the program MS
[31] and, following the suggestion in the documentation, replaced
the standard C random number generator with the well-known
and highly robust Mersenne-Twister random number generator
[34]. All variants generated by MS are biallelic because it assumes
the infinite-sites model of mutation.
Disease Model
Disease risk for the multi-variant genotype Gk was determined
according to a logistic penetrance model of the form:
PA jGk ðÞ ~ 1zexp {a{GkB ðÞ ðÞ
{1 ð2Þ
where a~ln f0= 1{f0 ðÞ ðÞ , the log odds of the wild-type penetrance
for the multi-variant genotype with no minor alleles at any risk
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T is the vector of log odds ratios for the
haplotype population. The odds ratio hj~exp bj
  
reflects the
increase in the odds of disease for each additional minor allele at
variant j. This model implicitly assumes that (1) each additional
minor allele has a multiplicative effect on the odds of disease and
(2) this effect at variant position j is independent of the effects at
other variant positions.
To parameterize this model, we specified the desired number of
risk variants as well as a set of risk variant classes indexed by c,
where class c was defined by a half-open MAF range, pl
c,pu
c
  
, and
an associated odds ratio, hc. For each haplotype population, the
vector of log odds ratios B was populated by repeating the
following steps until the specified number of risk variants was
selected:
1) A variant j was randomly selected from among the variants in
the haplotype population;
2) If the randomly selected variant j had a population MAF in
the interval pl
c,pu
c
  
specified for risk variant class c and had
not already been designated a risk variant, then it was labeled
a risk variant and assigned a coefficient bj~ln hc ðÞ .
This procedure effectively randomly samples risk-variant classes
from the haplotype population in proportion to the occurrence of
each MAF range in the population. All neutral variants had bj=0
(hc=1).
Case-Control Samples
After the vector of log odds ratios B was populated for a
haplotype population, a case-control sample was generated
according to the disease model. To generate a case-control
sample, the following procedure was repeated until the user-
specified numbers of case and control subjects were selected:
1) Haplotypes were randomly drawn with replacement to form
an individual’s multi-variant genotype Gk;
2) The disease risk of the individual’s multi-variant genotype,
P(A|Gk), was then calculated according to the logistic model
in (2);
3) The individual was randomly assigned affection status A with
probability P(A|Gk)o rC with probability 1-P(A|Gk).
Our method of forming Gk by randomly drawing haplotypes
with replacement implicitly assumes random mating in the
population.
Missing Genotypes
For each case-control sample, data sets with different rates of
randomly missing genotypes were generated based on user-
specified per-base-pair call rates. The observation process over
the sequence was modeled as a two-state Markov chain with states
‘‘observed’’ (O) or ‘‘missing’’ (M) at each position defined by a
single base pair. Given a call rate of l,1 per base pair, the
number of base pairs that a chain remains in M before a genotype
is called is distributed Exp(l), assuming a sufficiently long sequence
for continuous measurement of base pair position to be
reasonable. At the position of this called genotype, the state of
the chain changes from M to O with probability 1. Because
genotypes are missing at a rate of 1-l per base pair, the number of
base pairs that the chain remains in O before a genotype is missing
is distributed Exp(1-l), and the chain transitions from O to M with
probability 1 at this position. If we rescale position to [0, 1] by
measuring in units of L base pairs, where L is the total sequence
length, the distance the chain remains in M is distributed Exp(Ll),
and the distance the chain remains in O is distributed Exp(L(1-l)).
It can be shown that the expected proportion of the sequence
length that a Markov chain with these transition rates and
probabilities spends in O is simply the call rate, l. Thus, for each
call rate, the following steps were performed in each individual to
generate the observed genotype data:
1) Starting at position 0 in O, a series of alternating O and M
intervals on the [0,1] scale were generated according to the
exponential transition distance distributions for the two-state
Markov chain with call rate l over a sequence of length L;
2) The genotypes of variants with [0,1] scaled sequence
positions not falling within an O interval were set to missing.
The observation process defined by this Markov chain is
independent of both affection status and underlying genotypes,
meaning that missing genotypes are missing completely at random
in the sense of Little and Rubin [18].
Association Testing
For each data set, several methods for association testing were
applied. To ensure comparability across data sets from a
population, the minor allele was determined based on the allele
frequencies in the haplotype population from which the case-
control sample was drawn. Variants that were monomorphic in a
given data set were excluded from the test. A test producing a p-
value rejected the null hypothesis in a data set at level a if the p-
value was less than or equal to a.
Single-variant Cochran-Armitage trend chi-square statistics
were calculated as T=N
Or
2, where N
O is the number of
individuals with observed genotypes at the variant and r is the
Pearson correlation coefficient between the number of minor
alleles at the variant and a case status indicator equaling 1 for cases
and 0 for controls across individuals with observed genotypes.
Locus-wide inference was then performed using these single-
variant statistics in accordance with three established methods.
The most widely known method is the BC-CA test presented
above, which uses a conservative approximation that does not
make efficient use of the single-variant information for joint
inference [17]. This test was implemented by rejecting the null
hypothesis in a replicate at level a if the maximum Cochran-
Armitage trend chi-square statistic (max T) in the locus was greater
than or equal to the Bonferroni-corrected quantile of the
asymptotic null x2
1 distribution. This Bonferroni-corrected quantile
was determined separately for each data set as x2
1,1{a=v, where v is
the number of polymorphic variants in the data set.
A second popular method involves performing locus-wide
inference based on the permutation null distribution of max T
[19], which is efficient because it does not use a conservative
approximation and accounts for the LD-induced correlations
between the single-variant T values [17]. It has also demonstrated
consistently good performance relative to other locus-wide tests in
simulations of candidate gene SNPs with realistic LD [19]. The
permutation null distribution of max T was obtained by repeatedly
randomly shuffling affection status labels, calculating all single-
variant T values, and recording the resulting value of the max T
statistic. Letting Qt denote the value of the max T statistic in
permutation t and Qobs denote the observed value in the sample,
the two-sided p-value is estimated from m permutations as [35]:
^ P PQ~
P m
t~1
IQ t§Qobs ðÞ z1
mz1
ð3Þ
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genotype or affection status, the Monte Carlo procedure described
above will correctly estimate the permutation null distribution and
yield a valid p-value. A Monte Carlo estimate of the two-sided p-
value was obtained from (3) with m=10,000 permutations. We will
refer to the inferential procedure based on the permutation p-
value of the max T statistic as the CA max test.
A final method involves performing locus-wide inference based
on the permutation null distribution of the sum of Cochran-
Armitage trend chi-square statistics (sum T) over the locus, which
is also efficient because LD-induced correlations between single-
variant T values are fully taken into account in the permutation
null distribution. Variations on this theme have been proposed for
candidate gene association studies [19] and GWAS [20,21].
Simulations of candidate gene SNPs with realistic LD found that
the approach based on Fisher’s method for combining p-values,
which is equivalent to a sum of nonnegative single-variant test
statistics, performed well relative to other multi-SNP approaches
when there were many variants in high LD [19]. A Monte Carlo
estimate of the two-sided p-value for the sum T statistic was
obtained using the same permutation procedure as for the CA
max test. We will refer to the inferential procedure based on the
permutation p-value of the sum T statistic as the CA sum test.
The CA sum test is also closely related to the SKAT and C-
alpha test. Let Uj be the score statistic U in (1) for a single variant j
with additive scores Xk~Gjk, and let vj be a pre-specified weight
for variant j. In the absence of covariates and with complete
genotype data, the SKAT statistic can be expressed as
QSKAT~
Pv
j~1 vjU2
j (see Text S1, Appendix C). The authors of
the SKAT suggest weights that are a function of a Beta(1,25)
density at the pooled sample MAF to increase the contributions of
rare variants to the overall sum [13]. With vj~1 for all j, QSKAT is
equivalent to the C-alpha statistic [13]. With vj~V^ a ar Uj
   {1,
where V^ a ar Uj
  
is the estimated null variance of the single-variant
Cochran-Armitage trend score statistic from (1), QSKAT is
equivalent to the sum T statistic (see Text S1, Appendix C). With
missing genotypes and vj~V^ a ar Uj
   {1, QSKAT remains equivalent
to sum T when the single-variant SKAT score statistics and vj are
calculated using all available genotype data at each variant (see
Text S1, Appendix C). Thus, the performance of the CA sum test
should also provide insight into newer tests that achieve their
robustness to neutral and protective variants by performing
inference on weighted sums of nonnegative single-variant test
statistics.
Our implementation of the CMC method [5] collapsed rare
variants having overall sample MAF#0.01 into an indicator
variable equaling 1 if any minor alleles were present and zero
otherwise. Common variants that were not collapsed were coded
as 0, 1, or 2 minor alleles, and the means of the random vectors
comprising the rare variant indicator and common variant minor
allele counts were compared between cases and controls using
Hotelling’s T
2 test.
One issue not considered in the paper proposing the CMC
method is that LD among common variants can induce linear
dependency in this random vector, which leads to a singular
covariance matrix. However, calculating Hotelling’s T
2 statistic
with any generalized inverse is equivalent to calculating the
statistic with a standard inverse on a full-rank subset of linearly
independent common variants (see Text S1, Appendix D).
Goodnight [36] provides an algorithm for automatically calculat-
ing a g2 generalized inverse and the dimension of the full-rank
subset without any prior knowledge of the full-rank subset. The
algorithm involves applying the G2SWEEP operator once to each
of the columns of the covariance matrix in succession. This
operator zeros the rows and columns corresponding to common
variants that are numerically linearly dependent on the previous
common variant minor allele counts and/or the rare variant
indicator. The effective number of linearly independent vector
elements, v, is thus automatically obtained by subtracting the
number of columns that are zeroed from the total number of
columns in the covariance matrix. The p-value is then calculated
using the Fv,N-v-1 approximation to the distribution of the
appropriately scaled Hotelling’s T
2 statistic calculated using the
g2 generalized inverse of the covariance matrix (see Text S1,
Appendix D).
Only individuals with complete genotype data at common
variants could be used in calculating Hotelling’s T
2. Provided
genotype data were complete at all common variants, individuals
with missing genotype data at rare variants could be used if at least
one minor allele was present for a variant with a non-missing
genotype because the coding of the rare variant indicator would be
1 regardless of the other variant genotypes. However, if an
individual did not have any minor alleles at any variants with non-
missing genotypes, the coding of the rare variant indicator was
ambiguous because it would depend on the values of the
unobserved genotypes. Therefore, such individuals also had to
be excluded from calculating Hotelling’s T
2. With large numbers
of exclusions, the F test for Hotelling’s T
2 often could not be
performed due to insufficient effective denominator degrees of
freedom (ddf) or was performed with only a very small number of
effective ddf. We considered only results from F tests with effective
ddf.4 in our Type I error and power estimates because (1) our
testing indicated that algebraically identical generalized inverses
could yield different numerical results with effective ddf#4 and (2)
the expectation and variance of the F distribution only exist for ddf
.2 and ddf .4, respectively [27].
Our implementation of the WSS method [6] followed the
description in the original paper with four modifications. First,
midranks were used to break ties in genetic scores when
calculating the case rank-sum statistic, W. Second, we used a
two-sided p-value. A one-sided p-value will only be well-powered
for a deviation from the null in which the cumulative number of
minor alleles at lower-frequency variants is higher in cases than
controls. However, any departure from the null of equal genotype
frequencies in cases and controls at the locus is of interest in
association testing, which is why the BC-CA, CA max, CA sum,
and CMC tests all use two-sided p-values. Therefore, one would
also want to be able to detect deviations in which controls have a
higher cumulative number of minor alleles at lower-frequency
variants, which is not possible with a one-sided WSS p-value. Such
deviations could arise in plausible situations, such as one in which
the minor allele of a rare risk variant with a strong effect appears
exclusively on a haplotype with few other minor alleles. Third, we
estimated the two-sided p-value directly from the permutation
distribution of W. Letting Wt denote the value in permutation t,
Wobs denote the observed value in the sample, and   W Wdenote the
mean of W over all m permutations, the two-sided p-value was
estimated from m=10,000 permutations as [35,37]:
^ P PWSS~
P m
t~1
IW t{   W W jj § Wobs{   W W jj ðÞ z1
mz1
Finally, missing single-variant genotypes, which were not consid-
ered in the paper proposing the WSS method, were not used in
estimation of the MAF in controls and were assigned values of 0 so
as not to contribute to the WSS in an individual. This procedure is
Reconsidering Association Tests for Sequence Data
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e30238equivalent to calculating the genetic score over only nonmissing
genotypes in each individual.
Results
Characteristics of Variants in Actual Sequence Data
We began by analyzing the MAF and LD distributions of
variants in actual sequence data from six candidate genes for
dilated cardiomyopathy. These genes spanned a total of 236,059
base pairs (bp), of which 53,466 bp were scanned for variation. A
total of 215 biallelic variants were identified in 184 Coriell samples
of white European ancestry, yielding approximately 4 variants per
kb scanned. We found no evidence against HWE (Monte Carlo
exact P$0.001) at 211 of these variants, which were carried
forward to the analysis of MAF and LD distributions.
More than half of variants had MAFs below 0.01, confirming
that a multitude of rare variants is likely to be a distinguishing
characteristic of sequence data (Figure 1, Panel A). In addition, the
majority of pairwise LD between variants within the same gene
was small and negative, with more than 75% of r values below 0
(Figure 1, Panel B). Pairwise LD between rare variants with
MAF#0.01 was even more concentrated in small negative values,
with 95% of values falling between r=20.0095 and r=20.0028.
These results confirmed in actual data predictions regarding the
sampling distribution of LD based on coalescent theory [14].
Although the negative pairwise r values between variants with
MAF#0.01 may seem small in magnitude, they are not
inconsistent with negative LD having a substantial impact on
pooling tests. First, the theoretical minimum for r between variants
with MAF#0.01 is rmin=20.0101, so many of these r values may
actually represent D9 values near 1 that would be considered
strong LD. Second, because neutral variants are far more
numerous than risk variants in the genome, an appreciably higher
MAF at a single risk variant in cases can mean slightly higher
MAFs at numerous neutral variants in controls when most r values
are negative. If truly neutral variants are not detected with high
sensitivity and filtered out prior to analysis, the cumulative case-
control MAF difference over this large number of neutral variants
can easily mask the cumulative case-control MAF difference over a
few risk variants. Therefore, small negative pairwise r values
between rare variants can have an appreciable effect on pooling
tests.
Impact of Neutral Variation in a Simple Model
We used a simple model to compare the power of the BC-CA,
collapsing, and summing tests to detect a locus-wide association
driven by a single rare risk variant in the presence of a single rare
neutral variant at varying levels of LD between the two variants.
Although the power of the collapsing and summing tests exceeded
the lower bound for the BC-CA test with larger positive r values in
small samples (N=500), the worst-case power of the BC-CA test
was greater than that of the collapsing and summing tests for all
r#0.08 under both models considered (Figure 2). Moreover, the
BC-CA test had a power advantage over an even larger range of r
values under the same models in moderate (r#0.34) and large
(r#0.52) samples (Figures S1 and S2). In our actual sequence data,
over 95% of r values between variants with MAFs in the range
considered in Figures 2, S1, and S2 (#0.01) fell below 0,
suggesting that the BC-CA test should enjoy a power advantage in
most practical situations.
We can explain the relationship between the power of the three
tests and r by first considering the properties of the BC-CA,
collapsing, and summing tests when r=1. In this situation, the
number of minor alleles at the neutral variant must always equal
the number of minor alleles at the risk variant because minor
alleles at both variants must appear on the same haplotype. Thus,
the multi-variant genotype frequencies are the same as the
genotype frequencies at the risk variant alone, and the scores are
Xk=1, 0, or 0 (collapsing) or Xk=0, 2, or 4 (summing) when
G2k=0, 1, or 2, respectively. Under these circumstances, the
collapsing and summing tests are equivalent to level a single-
variant Cochran-Armitage tests for the risk variant using scores for
a dominant model and an additive model, respectively. Because
these tests are not Bonferroni corrected, their power when r=1is
Figure 1. MAF and within-gene pairwise LD distributions in actual sequence data. Distributions of MAFs (Panel A) and within-gene
pairwise LD (Panel B) for biallelic variants in six candidate genes for dilated cardiomyopathy. Pairwise LD was measured by the correlation coefficient
(r) between major/minor alleles for variants within the same gene. These distributions were estimated from 184 Coriell samples of European descent.
The vertical dashed line in Panel B indicates r=0.
doi:10.1371/journal.pone.0030238.g001
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based on a level a/2 single-variant Cochran-Armitage test for the
risk variant using scores for an additive model.
However, as r decreases, the amount of noise introduced into
the collapsing and summing test statistics by including the neutral
variant increases and results in a concomitant decrease in power.
Moreover, the problem of masking by the rare neutral variant
further reduces power when r,0. The worst-case power of the
BC-CA test, which inefficiently combines single-variant test
statistics, was substantially greater than the power of the collapsing
and summing tests for r,0, which is where over 95% of the r
values between variants with MAF#0.01 fell in our actual
sequence data. These results suggest that, by eliminating the
problems of noise and masking, even inefficient techniques for
locus-wide inference using nonnegative single-variant test statistics
can yield more powerful tests for association than pooling minor
alleles in the presence of rare neutral variants.
Monte Carlo Simulations
Monte Carlo simulations were performed to extend the analytic
power results to more realistic situations. These simulations were
based on case-control samples generated at a hypothetical 100 kb
disease locus with heterogeneous risk alleles, extensive neutral
variation, realistic patterns of LD, and randomly missing
genotypes.
The variants in our populations of haplotypes simulated based
on a coalescent model closely resembled those analyzed in our
actual sequence data. First, the rates of variants per kb were
compatible when the sampling process that generated our actual
sequence data was taken into account. Each simulated population
had an average of 981 variant sites (range: 805–1193) over the
100 kb locus, or approximately 10 variants per kb. While this rate
was somewhat higher than the observed rate of 4 variants per kb
scanned in our actual sequence data, it was not inconsistent with
this observation because fewer variants are expected to be
observed in any small sample from a large population. In fact,
an average of only 747 variants, or 7.5 per kb, appeared in samples
of 500 individuals drawn from these haplotype populations under
a null disease model with complete genotype data. A further
reduction in the number of variants per kb would be expected in a
sample of the same size as our actual sequence data, which was
about one-third the size of our smallest simulated samples.
Second, the variant MAF and pairwise LD distributions across
the populations of simulated haplotypes (Figure S3) closely
resembled those across the six candidate genes for dilated
cardiomyopathy (Figure 1). The only noticeable difference
between the MAF distributions occurred in the lower quantiles
because the sample MAF could not fall below 1/368=0.002717 in
the actual sequence data. The distributions of pairwise LD,
measured by the correlation coefficient, were also similar, with a
strong resemblance between the histograms and a close corre-
spondence between the quantiles for actual and simulated data.
These results suggested that variants in the average simulated
haplotype population had similar MAF and LD spectra to variants
in the average resequenced dilated cardiomyopathy candidate
gene.
We evaluated the performance of the BC-CA, CA max, CA
sum, CMC, and WSS tests in samples drawn from these haplotype
populations according to different disease models. For each disease
model, we considered balanced case-control samples with N=500,
N=1,000, and N=2,000; call rates of 100% (complete data),
99.5%, and 95%; and a=0.05 and 0.01.
Under a null model with no risk variants, all techniques
controlled type I error at the nominal level (Figure 3). The 95%
confidence intervals for the CA max, CA sum, and WSS all
contained the nominal a level under nearly all conditions,
reflecting an observed distribution of p-values extremely close to
the uniform expected under the null hypothesis. The CMC based
on Hotelling’s T
2 was often conservative in complete data, with
95% upper confidence limits below the nominal a level. Our result
agreed with that of Li and Leal [5], who observed conservatism
increasing with the number of variants analyzed when applying
Hotelling’s T
2 to a random vector containing between 5 and 20
rare variants in balanced case-control samples of sizes 500 and
Figure 2. Analytic power comparisons in a small sample (N=500). Analytic locus-wide power at a=0.05 of the BC-CA (lower bound),
collapsing, and summing tests at a locus comprising one neutral and one risk variant as a function of the pairwise correlation coefficient between
major/minor alleles (r). The variants had the same MAF=0.005 (Panel A) or MAF=0.01 (Panel B), and the relative risk was 3 (Panel A) or 2 (Panel B) for
each additional minor allele at the risk variant. Both panels assume penetrance of 0.05 for the major allele homozygote at the risk variant and a
balanced case-control sample with N=500 total subjects.
doi:10.1371/journal.pone.0030238.g002
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2 was applied to a
much larger vector containing at least 110 effectively linearly
independent elements in all data sets with complete genotype data.
Finally, the BC-CA test nearly always had the lowest Type I error
of all tests considered, reflecting conservatism due to failure to
account for LD-induced correlations between single-variant test
statistics.
The type I error results for the CMC with missing genotypes
also reflect the substantial loss of sample information resulting
from having to exclude all individuals with incomplete genotype
data at common variants. With a call rate of 95%, no type I error
rate could be estimated because no individual had complete data
in any of the 1,000 samples and the CMC could not be performed.
With a call rate of 99.5%, about 92% of individuals in the
average sample were unusable due to missing genotype data for
each sample size. For this reason, only 23 of the 1,000 samples
had reliable F tests with ddf.4f o rN=500, and the type I error
rate estimates for both a levels had wide 95% confidence
intervals.
Under a disease model with 50 rare risk variants (MAF,0.005;
OR=3), which represent ,5% of all variants in the locus in the
average haplotype population, the CA max test had higher power
than the CMC and WSS tests under all conditions (Figure 4). It
also had power comparable to or higher than the CA sum test,
Figure 3. Simulated type I error rate comparison. Monte Carlo estimates of rejection rates for each association testing procedure based on
1,000 samples from a null disease model with no risk variants. Estimates are reported by call rate, nominal a level, and sample size (N). Error bars
represent exact binomial 95% confidence intervals [39] for the rejection rate, and dashed horizontal lines are included at the nominal a level. The CMC
could not be performed at a call rate of 95% because no individual had complete genotype data in any sample; at a call rate of 99.5%, CMC results
with F ddf.4 were available in 23, 619, and 992 samples for N=500, 1,000, and 2,000, respectively.
doi:10.1371/journal.pone.0030238.g003
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additive genetic model without covariates using the inverse of the
estimated null variances of the score statistics as weights. As
expected, the CA max test substantially outperformed the BC-CA
test, which does not account for LD-induced correlations between
test statistics. As the sample size grew, the power of the CMC test
with complete data approached that of the CA max test. With
missing data, however, the CMC test generally had the lowest
power due to the substantial loss of sample when it could even be
performed. The CA sum test was more powerful than the CMC
test under most conditions, but it began to lag the CMC in
complete data for N$1,000. The CA sum test was always more
powerful than the WSS test. Although the CA sum test was more
powerful the BC-CA test under all scenarios with a=0.05, its
power deteriorated to below that of the BC-CA test in larger
sample sizes with a=0.01.
Although the WSS test was more powerful than the BC-CA test
when N=500, it began to lag the BC-CA test for N$1,000,
sometimes substantially. This observation suggests that, when
summing over minor alleles to reduce the number of tests
performed, the power gain from reducing the multiple-testing
penalty was rapidly outweighed by the power loss due to increased
noise and masking as the sample size grew. The WSS test also had
lower power than the CMC test in most scenarios with complete
data. Because the CMC test collapses over only variants with
MAF#0.01 and analyzes common variants in a manner not
Figure 4. Simulated power comparison for rare risk variants (MAF,0.005; OR=3). Monte Carlo estimates of rejection rates for each
association testing procedure based on 1,000 samples from a disease model with 50 rare risk variants (MAF,0.005; OR=3), which represent ,5% of
all variants in the locus in the average population. Estimates are reported by call rate, nominal a level, and sample size (N). Error bars represent exact
binomial 95% confidence intervals [39] for the rejection rate. The CMC could not be performed at a call rate of 95% because no individual had
complete genotype data in any sample; at a call rate of 99.5%, CMC results with F ddf.4 were available in 22, 596, and 991 samples for N=500, 1,000,
and 2,000, respectively.
doi:10.1371/journal.pone.0030238.g004
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which sums over all variants.
Results were similar under a disease model with 50 rare risk
variants (MAF,0.01; OR=2) (Figure 5). The CA max test had
power greater than the CA sum, CMC, WSS, and BC-CA tests
under all scenarios. The CA sum test continued to have higher
power than the WSS test under all scenarios and was also more
powerful than the CMC test for all conditions except N=2,000
with complete data. The CA sum test was more powerful than the
BC-CA test under all conditions other than N=2,000 and
a=0.01. The WSS test also exhibited a similar pattern of
performance relative to the CMC and BC-CA tests.
In the disease model with 50 total risk variants randomly
allocated between rare variants (MAF,0.01; OR=2), low-
frequency variants (0.01#MAF,0.05; OR=1.5), and common
variants (0.05#MAF,0.10; OR=1.2), the CA max and CA sum
tests were both more powerful than the CMC and WSS tests
under nearly all conditions (Figure 6). Under this disease model,
the CA sum test, rather than the CA max test, had the highest
power under all conditions. The CA max and CA sum tests also
both had greater power than the BC-CA test in all scenarios. With
N=2,000 and complete data, the CMC test had comparable
power to the CA max test but was still less powerful than the CA
sum test. The WSS test showed the same pattern of having higher
Figure 5. Simulated power comparison for rare risk variants (MAF,0.01; OR=2). Monte Carlo estimates of rejection rates for each
association testing procedure based on 1,000 samples from a disease model with 50 rare risk variants (MAF,0.01; OR=2), which represent ,5% of all
variants in the locus in the average population. Estimates are reported by call rate, nominal a level, and sample size (N). Error bars represent exact
binomial 95% confidence intervals [39] for the rejection rate. The CMC could not be performed at a call rate of 95% because no individual had
complete genotype data in any sample; at a call rate of 99.5%, CMC results with F ddf.4 were available in 18, 573, and 986 samples for N=500, 1,000,
and 2,000, respectively.
doi:10.1371/journal.pone.0030238.g005
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to lag these tests for N$1,000.
Discussion
We have compared existing methods for efficient locus-wide
inference using nonnegative single-variant test statistics to two
widely cited pooling tests in terms of their ability to detect
associations between rare variants and disease. We began our
analysis by exploring the characteristics of variants likely to
appear in actual sequence data. Based on these characteristics
and a simple model of a locus with one rare risk and one rare
neutral variant, we were able to demonstrate that even using
Bonferroni-corrected single-variant tests for locus-wide inference
may have higher power than collapsing or summing rare variant
minor alleles in the presence of a neutral variant. We then
simulated populations of haplotypes at a hypothetical 100 kb locus
with MAF and LD spectra closely matching those of our actual
candidate gene sequence data. We examined power in balanced
case-control samples drawn from these simulated haplotype
populations according to a disease model with heterogeneous risk
alleles and extensive neutral variation. In these simulations, one or
more of the existing approaches for efficient locus-wide inference
using nonnegative single-variant test statistics, the CA max test or
Figure 6. Simulated power comparison for a mixture of rare and common risk variants. Monte Carlo estimates of rejection rates for each
association testing procedure based on 1,000 samples from a disease model with 50 total risk variants, which represent ,5% of all variants in the
locus in the average population, randomly allocated between rare variants (MAF,0.01; OR=2), low-frequency variants (0.01#MAF,0.05; OR=1.5),
and common variants (0.05#MAF,0.10; OR=1.2). Estimates are reported by call rate, nominal a level, and sample size (N). Error bars represent exact
binomial 95% confidence intervals [39] for the rejection rate. The CMC could not be performed at a call rate of 95% because no individual had
complete genotype data in any sample; at a call rate of 99.5%, CMC results with F ddf.4 were available in 15, 564, and 989 samples for N=500, 1,000,
and 2,000, respectively.
doi:10.1371/journal.pone.0030238.g006
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and WSS tests under the scenarios considered. Moreover, the type
I error and power of the CA max and CA sum tests were robust to
randomly missing genotype data, which was not observed with the
CMC test. Finally, the CA max test was nearly always more
powerful than the CA sum test for disease models with only rare
risk variants, suggesting that the CA max test may outperform the
class of techniques represented by the SKAT and C-alpha test in
these scenarios.
Our results contradict those of the original studies [5,6]
suggesting that the CMC and WSS tests were superior to locus-
wide inference using nonnegative single-variant test statistics.
However, our simulations improve upon these studies in two
important ways that explain the differences in results and make
our results more relevant to the analysis of actual sequence data.
First, we used a widely accepted population genetic model, the
coalescent, to simulate variants with MAF and LD distributions
similar to those in actual sequence data, meaning that our
simulations should more accurately reflect the impact of neutral
variants on each method. Although the CMC study did consider
the impact of including neutral variants, it used analytic power
calculations that assumed independence between genotypes at
different variant sites [5]. The study also considered only models
with fixed numbers of variants of different types having equal
MAFs within each type. The WSS study considered only MAF
spectra consistent with mildly deleterious mutations and sampled
each variant, whether risk or neutral, independently of all others
[6]. Neither of these methods is likely to recapitulate the rich
complexity of the variant MAF and LD distributions that we
observed in actual sequence data as well as our coalescent-based
approach did. Moreover, simulated data without many higher-
frequency neutral variants or substantial LD between neutral and
risk variants would tend to cause fewer problems with noise and
masking in pooling tests, resulting in overly optimistic assessments
of the performance of these techniques. In fact, we found that the
WSS test was often less powerful than even the inefficient BC-CA
test, suggesting that noise and masking from neutral variants may
present major problems for techniques based on summing in
actual sequence data.
Second, we used efficient methods for locus-wide inference
based on nonnegative single-variant test statistics that reduce the
multiple-testing penalty by accounting for LD-induced correla-
tions between the single-variant test statistics. However, the CMC
and WSS tests were both compared in the original studies to the
Bonferroni and Dunn-Sidak corrections [5,6], which are both
generally conservative. Although the choice to assume indepen-
dence between variants should mean that the Dunn-Sidak
correction was efficient in the original WSS study, the Bonferroni
correction used in the original CMC study should still have been
conservative and thus inefficient under these conditions. In our
more realistic simulated data, LD would have induced correlations
between test statistics at different variants, which would have
rendered both of these techniques more conservative [17]. In such
situations, methods based on simulating the joint distribution of p-
values or test statistics under the locus-wide null hypothesis yield
more powerful locus-wide tests [17] and are the relevant targets for
comparison. The CA max test used in this paper is one such
method, and it outperformed the BC-CA test under every scenario
considered in our simulations while controlling the Type I error
rate, as predicted by theory. Thus, the CA max test, which is
simple and computationally feasible, provides a fairer representa-
tion of the performance of existing methods for efficient locus-wide
inference using nonnegative single-variant test statistics in actual
sequence data.
These methods also make use of all available genotype data and
are therefore robust to randomly missing genotypes. This
robustness stands in stark contrast to our observations for the
CMC test using Hotelling’s T
2, which rapidly became unreliable
with as little as 0.5% randomly missing genotypes. Other
multivariate techniques that rely on a generalized linear model
framework, such as the SKAT, will also be subject to the same
problem because generalized linear models can only use
individuals with complete data. Although all individuals’ data
could be made complete by imputing missing genotypes, low-
frequency or rare variants may be difficult to impute with high
accuracy. One caveat to our robustness result is that any method
relying on the permutation null distribution for inference, which
includes the CA max, CA sum, and WSS tests, will only be valid if
genotype missingness does not depend on either affection status or
the unknown value of the underlying genotype. In other words,
genotypes must be missing completely at random in the sense of
Little and Rubin [18]. If this is not the case, affection status is not
exchangeable under the genetic null hypothesis, meaning that
permutation inference may not yield valid results.
The problem of neutral and protective rare variants masking
case-control differences in pooling tests has been recognized by
other authors [8–13]. Many new developments have therefore
sought to reduce the influence of putative neutral and protective
variants using filtering, classification, or weights based on
annotation, functional predictions, or MAFs [8–11,13]. While
these approaches seem sensible, there are several drawbacks. First,
annotation and functional predictions are not readily available for
non-coding sequences that may influence disease through recently
discovered or as-yet-unknown regulatory mechanisms. Second, as
demonstrated by recent examples implicating synonymous coding
variants in altered protein products and Crohn’s disease [15,16],
annotation and functional predictions for coding sequences do not
always provide a solid basis on which to separate putative risk,
neutral, and protective variants a priori. Finally, distinguishing
neutral and protective variants based on sample MAFs alone [11]
will be prone to error because of sampling variability, particularly
with rare variants. In contrast, methods for locus-wide inference
using nonnegative single-variant test statistics are inherently robust
to the inclusion of neutral and protective variants and may even be
able to exploit their LD with risk variants to increase power.
Notably, the power advantage of the CA max and CA sum tests
observed in this study did not require any information or
assumptions about the putative functional consequences of the
minor allele in relation to the disease of interest. Thus, the CA
max or CA sum tests could be applied equally well to coding
sequence, non-coding sequence with poorly understood functional
consequences, or a combination thereof.
An additional advantage of applying existing methods for locus-
wide inference using nonnegative single-variant test statistics is
their adaptability. Although we have focused on single-locus
inference for concreteness, test statistics can be combined over any
relevant grouping of variants, including single exons, pathways, or
the entire exome, to perform joint inference. Pooling tests can also
be applied to arbitrary groupings, but they are not inherently
robust to the inclusion of neutral and protective variants.
Moreover, although we focused on case-control association testing
in the absence of confounding and population stratification,
existing methods using nonnegative single-variant test statistics can
be readily extended to multi-variant joint inference in more
complex case-control or family-based designs by simply changing
the test statistic and permutation strategy. As long as the new test
statistic has a nonnegative value that depends only on the
magnitude of the deviation from the statistical null hypothesis at
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inclusion of neutral and protective variants. The permutation
strategy would then need to be adapted to ensure exchangeability
under the model implied by the new single-variant test statistic
(see, e.g., McIntyre et al. [38] for a permutation strategy valid for
the transmission/disequilibrium test statistic in a trio design).
Finally, although we considered only the maximum and sum of
Cochran-Armitage trend chi-square statistics over the variant
grouping of interest, almost any summary of a wide variety of
nonnegative single-variant test statistics could be used for joint
inference based on the appropriate permutation distribution.
Although the idea of pooling minor alleles in association tests
with rare variants may still hold sway in the genetics community, it
is worth noting that some new association tests with greater
robustness to the inclusion of neutral and protective variants have
implicitly returned to locus-wide inference using nonnegative
single-variant test statistics. Specifically, the SKAT [13] and C-
alpha test [12] are equivalent to basing inference on weighted and
unweighted sums of squared single-variant score statistics,
respectively [13]. The sum T statistic evaluated in this study is
also a sum of squared single-variant score statistics weighted by the
inverse of their estimated null variances. Our results for the CA
sum test, combined with the results of the studies proposing the
SKAT and C-alpha test [12,13], suggest that further extending
methods for locus-wide inference using nonnegative single-variant
test statistics may be a fruitful line of research. Moreover, a
method in this class fundamentally different from the closely
related SKAT, C-alpha test, and CA sum test—the CA max test—
often had greater power than the CA sum test for disease models
with only rare risk variants. We therefore suggest that a conceptual
framework based on optimally combining nonnegative single-
variant test statistics may yield useful insights or suggest other
existing techniques that might be overlooked within a conceptual
framework based on pooling minor alleles.
Supporting Information
Figure S1 Analytic power comparisons in a moderate
sample (N=1,000). Analytic locus-wide power at a=0.05 of
the BC-CA (lower bound), collapsing, and summing tests at a locus
comprising one neutral and one risk variant as a function of the
pairwise correlation coefficient between major/minor alleles (r).
The variants had the same MAF=0.005 (Panel A) or MAF=0.01
(Panel B), and the relative risk was 3 (Panel A) or 2 (Panel B) for
each additional minor allele at the risk variant. Both panels assume
penetrance of 0.05 for the major allele homozygote at the risk
variant and a balanced case-control sample with N=1,000 total
subjects.
(PNG)
Figure S2 Analytic power comparisons in a large
sample (N=2,000). Analytic locus-wide power at a=0.05 of
the BC-CA (lower bound), collapsing, and summing tests at a locus
comprising one neutral and one risk variant as a function of the
pairwise correlation coefficient between major/minor alleles (r).
The variants had the same MAF=0.005 (Panel A) or MAF=0.01
(Panel B), and the relative risk was 3 (Panel A) or 2 (Panel B) for
each additional minor allele at the risk variant. Both panels assume
penetrance of 0.05 for the major allele homozygote at the risk
variant and a balanced case-control sample with N=2,000 total
subjects.
(PNG)
Figure S3 MAF and pairwise LD distributions in
simulated sequence data. Distributions of MAFs (Panel A)
and pairwise LD (Panel B) for biallelic variants in 1,000
populations of 10,000 simulated haplotypes each at a 100 kb
locus. Pairwise LD was measured by the within-gene pairwise
correlation coefficient (r) between major/minor alleles. Because it
was computationally infeasible to summarize hundreds of millions
of pairwise LD values, a 0.1% simple random sample of these
values was taken from each haplotype population. We repeated
this sampling procedure several times and obtained similar results.
The vertical dashed line in Panel B indicates r=0.
(PNG)
Text S1 Appendices.
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